HPLC · CoA
Retatrutide vs Semaglutide vs Tirzepatide: What Is the Difference?
Comparison · 7 min read · Updated 30 September 2026
The difference between retatrutide, semaglutide and tirzepatide is the number of hormone receptors each molecule activates. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide engages two receptors, GIP and GLP-1. Retatrutide adds the glucagon receptor to those two, which makes it a triple agonist. All three are lipidated peptides engineered to bind serum albumin, which is why each has a reported plasma half-life measured in days.
For a laboratory, the selection turns on which signalling pathways a study must isolate, not which compound is stronger. Macropus Peptides supplies retatrutide and tirzepatide as lyophilised research material; semaglutide is not part of our range. Laboratories sourcing the triple agonist can order it from the Retatrutide product page, which lists the 10mg, 15mg, 20mg and 30mg vials with a certificate of analysis for each lot.
Is Retatrutide a GLP-1 Agonist?
Retatrutide is a GLP-1 receptor agonist, but it is not a GLP-1 analogue in the sense that semaglutide is. Its 39 amino acid backbone was derived from the GIP sequence and then modified so that a single chain also activates the GLP-1 and glucagon receptors. The discovery paper, published in Cell Metabolism in 2022 under the development code LY3437943, described a molecule several times more potent than native GIP at the GIP receptor and less potent than the native hormones at the GLP-1 and glucagon receptors. That deliberate imbalance is the property most in-vitro studies set out to characterise.
Semaglutide, by contrast, is a 31 residue analogue of human GLP-1(7-37). An alpha-aminoisobutyric acid at position 8 protects it from dipeptidyl peptidase-4, and a C18 fatty diacid attached through a linker at lysine 26 supplies albumin binding. It activates the GLP-1 receptor alone.
Retatrutide vs Semaglutide vs Tirzepatide at a Glance
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1 receptor | Agonist | Agonist | Agonist |
| GIP receptor | No activity | Agonist, strongest target | Agonist, strongest target |
| Glucagon receptor | No activity | No activity | Agonist |
| Backbone | GLP-1 based | GIP based | GIP based |
| Length | 31 residues | 39 residues | 39 residues |
| Approximate molecular weight | 4,114 Da | 4,814 Da | 4,731 Da |
| Albumin-binding chain | C18 diacid | C20 diacid | C20 diacid |
| Reported plasma half-life | About 7 days | About 5 days | About 6 days |
| Development stage | Registered medicine in Australia and overseas | Registered medicine in Australia and overseas | Phase 3, not registered anywhere |
| Supplied by Macropus Peptides | No | Yes, 20mg and 40mg vials | Yes, 10mg to 30mg vials and pens |
Half-lives are those reported in published human pharmacokinetic studies. They describe clearance from plasma, not stability of the lyophilised powder or of a reconstituted solution.
What Does Each Receptor Contribute to a Study?
Each receptor contributes a distinct signalling pathway, so the receptor profile of a compound defines which physiological questions a study using it can address.
GLP-1 receptor
GLP-1 is secreted by intestinal L cells after nutrient intake. At its receptor on pancreatic beta cells it amplifies glucose-dependent insulin secretion, and receptors in the brain and gut are studied for their role in satiety signalling and gastric emptying. All three compounds reach this receptor, so it forms the shared baseline of any comparison.
GIP receptor
GIP is released by K cells in the proximal small intestine. It also potentiates insulin secretion, and its expression on adipocytes makes it a subject of fat tissue research. The contribution of GIP agonism remains debated, since some studies report comparable metabolic readouts with GIP receptor antagonism, which is one reason dual and triple agonists are valuable experimental tools.
Glucagon receptor
The liver is the principal glucagon target, where the hormone increases hepatic glucose output and fatty acid oxidation, and the receptor is examined for its role in energy expenditure. Glucagon agonism alone raises blood glucose, so combining it with incretin signalling is what makes a triple agonist coherent as a design. Retatrutide is the only compound of the three that activates it.
Which Is Better for Research, Tirzepatide or Retatrutide?
Neither compound is better in a general sense, because tirzepatide and retatrutide are designed to answer different research questions. A protocol asking what glucagon receptor signalling adds on top of combined GIP and GLP-1 agonism would pair tirzepatide in 20mg or 40mg vials as the dual agonist control with retatrutide as the triple agonist, and add a GLP-1-only arm where one is available. Both share a GIP-based backbone and a C20 diacid chain, so differences between them are more readily attributed to receptor profile than to pharmacokinetics.
How Far Has Each Compound Progressed in Clinical Trials?
Semaglutide and tirzepatide are registered medicines, while retatrutide remains in phase 3 trials and is registered nowhere. Semaglutide has the longest record, with phase 3 results published from 2016. Phase 3 data for tirzepatide appeared in NEJM from 2021 onward. Retatrutide completed a phase 1b study that The Lancet carried in 2022 and a phase 2 study that NEJM carried in 2023, and its phase 3 programme is running overseas. None of this alters how our material may be used: every vial is supplied for in-vitro laboratory research only.
Do Retatrutide and Semaglutide Differ in Laboratory Handling?
Retatrutide and semaglutide are handled in much the same way, but they differ in molecular weight, which matters whenever studies compare them by amount. Both are supplied as white lyophilised powder, both dissolve readily in bacteriostatic water, and both are stored sealed at -20 °C and at 2 to 8 °C once reconstituted. Retatrutide is the heavier molecule, so one milligram contains fewer moles of peptide. A retatrutide vs semaglutide study that matches arms by mass alone is not matching them by molar receptor exposure, and the correction should be written into the protocol. In-use limits for reconstituted stock are set out in how long retatrutide lasts once mixed.
How Does Cagrilintide Differ From Semaglutide?
Cagrilintide differs from semaglutide in that it is an amylin analogue acting at amylin and calcitonin receptors, and it shares no receptor with semaglutide at all. Beta cells release native amylin, a peptide of 37 residues, together with insulin. Its receptors are heterodimers: the calcitonin receptor coupled to RAMP1, RAMP2 or RAMP3, the three receptor activity-modifying proteins. The peptide in our lipidated cagrilintide research vials acts at these complexes and at the calcitonin receptor alone. Because the two pathways do not overlap, the pairing was evaluated in a phase 2 study reported in The Lancet in 2023. Laboratories examining the amylin pathway alongside a triple agonist can use the Retatrutide and Cagrilintide 15mg blend, which combines both peptides in one vial.
Where tesamorelin fits
Tesamorelin appears in metabolic research but belongs to a separate signalling system. It is a GHRH analogue that acts through the pituitary GHRH receptor and has no activity at incretin or glucagon receptors, so it is not a comparator for any of the three compounds.
Choosing a Compound for a Protocol
- GLP-1 receptor alone: a selective agonist such as semaglutide, which we do not supply
- GIP and GLP-1 receptors: tirzepatide
- GIP, GLP-1 and glucagon receptors: retatrutide
- Amylin pathway alongside incretin signalling: cagrilintide, alone or blended with retatrutide
Each of these compounds sits within our metabolic research peptide category, HPLC tested to 98% or higher with identity confirmed by mass spectrometry. Our recommendation is to select by receptor profile first and design the control arms around it, so that any recorded difference can be traced to a single pathway. For laboratories that have settled on the triple agonist, the Retatrutide vials and pens page is where to buy it.
Questions about retatrutide vs semaglutide
Sources
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023.
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020.
- Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.